<DOC>
	<DOCNO>NCT02601729</DOCNO>
	<brief_summary>Type 1 diabetes mellitus ( T1DM ) autoimmune disease cause immune mediate destruction pancreatic β-cells . Once pancreas deplete critical mass β-cells need exogenous insulin therapy emerge . Several method exist administer insulin . An alternative way administer insulin mean continuous subcutaneous insulin infusion ( CSII ) insulin-pump therapy.The frequent execution self-monitoring blood glucose ( SMBG ) accomplish capillary finger-stick test essential management diabetes , limit also lacks information rise fall trend actual glycaemia . A solution use Real-Time Continuous Glucose Monitoring ( RT-CGM ) device . Contrary SMBG , RT-CGM measure glycaemia 24 hour day , provide information glucose direction rate change multiple day week . Since September 2014 , RT-CGM reimburse Belgium select group type 1 diabetic patient mean so-called `` CGM convention '' . The main objective study evaluate impact real time continuous glucose monitoring reimbursement real-life clinical care parameter type 1 diabetic patient Belgium 12 24 month .</brief_summary>
	<brief_title>Reimbursement Study Continuous Glucose Monitoring Belgium</brief_title>
	<detailed_description />
	<criteria>Patients T1DM include RTCGM reimbursement system follow one 17 diabetes center . Patients include RTCGM reimbursement system .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>real-time continuous glucose monitoring</keyword>
	<keyword>observational study</keyword>
	<keyword>insulin pump</keyword>
	<keyword>Belgium</keyword>
</DOC>